Tango Therapeutics Inc at Cowen Health Care Conference Transcript
Good morning, everyone. I'm Barbara Weber. I'm the CEO of Tango Therapeutics, and I'm going to walk you through a little bit about our lead program this morning. Just to start, Tango is a clinical-stage precision oncology company that was started to address the issue of tumor suppressor gene loss in cancers using synthetic lethality.
We were all used to the idea of targeting activated oncogenes, but until the ability to identify synthetic lethal targets was really made possible at scale through the discovery of the CRISPR technology, there's been very little that's been able to be done outside of the PARP space thinking about tumor suppressor gene loss in cancers.
We launched in 2017 and have built a CRISPR-based, truly state-of-the-art functional genomics platform to discover synthetic lethal targets to a whole range of different tumor suppressor gene loss events and now have a pretty extensive pipeline coming from that platform. We are in dose escalation with our first program, TNG908, which is a synthetic PRMT5 inhibitor that is synthetic
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
